Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Orchestra Biomed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of their collaboration agreement, Orchestra BioMed and Terumo plan to execute a global clinical program Virtue SAB (sirolimus), in an effort to gain regulatory approval for commercial sale of Virtue SAB in multiple markets and indications...
Brand Name : Virtue SAB
Molecule Type : Small molecule
Upfront Cash : $30.0 million
July 05, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Orchestra Biomed
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?